A Study of CIN-107 in Adults With Primary Aldosteronism

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

October 28, 2024

Study Completion Date

October 28, 2024

Conditions
Primary AldosteronismHyperaldosteronism
Interventions
DRUG

CIN-107 2 mg dosing

One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.

DRUG

CIN-107 4 mg dosing

Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.

DRUG

CIN-107 8 mg dosing

Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.

Trial Locations (10)

21287

Research Site, Baltimore

43210

Research Site, Columbus

45245

Research Site, Cincinnati

48109

Research Site, Ann Arbor

55905

Research Site, Rochester

60611

Research Site, Chicago

90048

Research Site, West Hollywood

94110

Research Site, San Francisco

94904

Research Site, Greenbrae

75390-9047

Research Site, Dallas

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY